Resources
69 Results (showing 31 - 40)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 7/13/2020 (updated 3/28/2024)
The Facts About Buprenorphine for Treatment of Opioid Addiction is available in many languages, including Spanish.
Posted 2/4/2020 (updated 3/28/2024)
How States are Responding to the Opioid Crisis: An Overview Webinar Presentation and Materials
Posted 9/14/2020 (updated 3/29/2024)
The RCORP-TA Policy Academy Town Hall took place on September 1, 2020.
Please find the presentation and recording posted here.
Posted 6/17/2021 (updated 4/2/2024)
Importance: Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking.
Objective:To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence
Posted 6/17/2021 (updated 4/2/2024)
Telemedicine is increasingly being used to treat patients with opioid use disorder (OUD). It has particular value in rural areas of the United States impacted by the opioid crisis as these areas have a shortage of trained addiction medicine providers. Patient satisfaction significantly impacts positive clinical outcomes in OUD treatment and thus is of great clinical interest.
Posted 7/7/2021 (updated 4/2/2024)
In 2015, 33,091 persons in the United States died from an opioid-related drug overdose.The epidemic of opioid overdose deaths has led to expanding the use of naloxone in community settings by non–medically trained bystanders who are often people who use drugs (PWUD). Since 2013, illicitly manufactured fentanyl (IMF), fentanyl analogs, and other synthetic opioids have played an increasing role in overdose deaths in the United States. Illicitly manufactured fentanyl (IMF) prevalence has increased. However, there is uncertainty about naloxone dose(s) used by nonmedical bystanders to reverse opioid overdoses in the context of increasing IMF.
Posted 7/19/2021 (updated 4/2/2024)
Drug overdose deaths in the United States hit a record high in 2017, with an estimated 72,000 deaths. Over two-thirds of those deaths, roughly 47,600, were due to opioids.These staggering numbers continued in 2018, as over 67,000 drug overdose deaths occurred, and opioids were involved in rough 46,800 of those overdose deaths.
This roadmap highlights existing state efforts and serves as a policy development tool for Governors and state officials seeking to improve coordination and bolster existing efforts across state agencies to address OUD among people involved in the justice system by expanding access to evidence-based medications.
Posted 7/19/2021 (updated 4/2/2024)
Buprenorphine/naloxone, an evidence-based treatment for opioid use disorder, is sometimes diverted for non-medical use. In Rhode Island, the prevalence of opioid use and, more recently, of fentanyl in the illicit drug supply is driving overdose fatalities, which increases the need for treatment and raises questions about the changing role of diverted medication in shaping overdose risk.
Posted 7/21/2021 (updated 4/2/2024)
RCORP-TA and federal experts provided updates on the process for obtaining and using a waiver to prescribe buprenorphine for the treatment of opioid use disorder with ample time for questions and answers from participants.
Presenter(s): Dr. Melinda Campopiano & Monica Rousseau, DrPH
Posted 7/28/2021 (updated 4/2/2024)
Various state and local jurisdictions in the United States are implementing mobile models for treating opioid use disorder (OUD). In August 2020, RTI International spoke with six agencies to learn more about their mobile treatment programs. This article is the first in a three-part series on mobile response programs and provides an in-depth look at two of these programs. We will discuss the remaining programs in two subsequent articles. The goal of this series is to inform jurisdictions considering whether a mobile treatment program would work in their communities and to determine what type of model would fit best.